Acute Postoperative Pain in an Opioid-Tolerant Patient: Building the Ward Regimen
A woman on long-term opioids for chronic pain needs an acute pain plan after surgery, and the hospital's standard postoperative order set is built for a patient who has never taken an opioid before — not for her.
S.A., a 45-year-old woman, has lived with chronic pain from severe endometriosis and multiple prior abdominal surgeries for over a decade, managed for the past four years on a stable regimen of long-acting morphine totaling roughly 90 MME daily, prescribed and monitored through the same pain clinic the entire time. She works as a middle-school teacher, structuring her sick days carefully around flare-ups she has learned to predict, and is now admitted for an urgent exploratory laparotomy after imaging suggested a possible bowel obstruction related to adhesions from her earlier surgeries. The surgery went as planned, uncomplicated, but the surgical team's standard postoperative order set — built, like most hospital order sets, around an opioid-naive patient's expected dosing needs — would leave her started well below what her body already requires just to avoid withdrawal, before any actual surgical pain is even factored in.
Her situation carries two real, distinct risks that a simple "give her more opioid than usual" instinct doesn't fully answer. The first is straightforward undertreatment if her home baseline isn't explicitly built into the acute plan — a tolerant patient given an opioid-naive starting dose will be in real, avoidable pain from the outset. The second is subtler and cuts against the instinct to simply escalate further: opioid-tolerant surgical patients carry a real, documented elevated risk of opioid-induced hyperalgesia, a state in which increasing opioid exposure produces a paradoxical heightening of pain sensitivity rather than relief, driven by central sensitization mechanisms distinct from simple undertreated nociception. Angst and Clark's 2006 qualitative systematic review is the standard reference for it, and it is candid about the part that matters most at S.A.'s bedside: the phenomenon is real, but it cannot be reliably distinguished from plain tolerance by clinical observation alone — which is exactly the discrimination her POD 0 regimen is about to be asked to make, at four years of stable exposure. Distinguishing which problem is happening — not enough opioid, or too much driving hyperalgesia — is exactly the kind of judgment call a ward regimen has to be built to actually make, not something a fixed order set can resolve by dose alone.
Inpatient pain service, POD 0 planning
First and most basic: her home baseline has to be built into the order set explicitly, continued through admission, with PCA opioid layered on top for the actual surgical pain. If we let the standard opioid-naive order set stand as written, she starts the admission already undertreated before surgical pain is even in the picture — that's not a subtle risk, it's a predictable one.
Agreed on the baseline, fully — that's not in question. What I want added is a low-dose ketamine infusion alongside it, not instead of it. Opioid-tolerant surgical patients carry a real, elevated risk of opioid-induced hyperalgesia, where escalating opioid doses can paradoxically make pain worse rather than better — and Angst and Clark were explicit back in 2006 that the bedside can't cleanly tell it apart from tolerance, which is why I don't want us resolving it by dose alone. If her pain control isn't improving as we titrate opioids up, ketamine's anti-hyperalgesic mechanism gives us a real tool that addresses that specific possibility directly, rather than just escalating the dose of a drug that might be contributing to the problem.
Continuing to raise opioid doses when the real driver might be hyperalgesia, not undertreatment, risks chasing the wrong mechanism with more of the same drug.
Both of your additions are right, and I want to make sure the non-opioid multimodal piece doesn't get treated as an afterthought once the baseline and ketamine questions are settled. Scheduled acetaminophen, an NSAID if no contraindication, and a regional block if the surgical team can place one — every one of those reduces the total opioid burden this regimen has to carry, which matters more for a tolerant patient at real OIH risk, not less, because it shrinks exactly the exposure the pharmacologist is worried about.
Treating multimodal analgesia as supplementary rather than central undersells how directly it addresses the hyperalgesia risk already on the table — it's not a separate, lower-priority track from the opioid and ketamine plan, it's part of the same strategy.
Agreed: home baseline morphine continued unchanged, hydromorphone PCA layered on top for acute pain, a low-dose ketamine infusion started for the first 48 hours specifically as an anti-hyperalgesic measure, and scheduled acetaminophen plus an NSAID for the non-opioid component. All three voices signed onto the combined plan, with the hospitalist's framing — that multimodal analgesia is central to managing OIH risk, not supplementary to it — accepted without contest by the other two.
Not fully settled: how the team would actually distinguish, at the bedside, between undertreated pain and emerging hyperalgesia if her reported pain worsened despite escalating PCA use over the following days. The anesthesiologist's working plan is to watch for pain that worsens with, rather than responds to, opioid escalation as the clinical tell; the pharmacologist agreed this is the right signal to watch but noted it can be genuinely hard to distinguish from simple undertreatment in real time, a limitation carried forward into her nursing documentation rather than resolved in advance.